KAZIA THERAPEUTICS LIMITED. Mediaroom

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and To...

2026-05-26 19:30 4858

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology...

2026-04-15 20:00 6390

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and met...

2026-01-30 21:00 10959

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical ...

2026-01-27 21:00 10017

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chi...

2026-01-08 22:00 8594

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance...

2025-12-22 21:00 7417

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions...

2025-12-10 21:00 7302

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused...

2025-12-02 22:00 4985

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focuse...

2025-11-19 05:15 4356

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today a...

2025-10-27 19:15 2518

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused...

2025-10-07 20:30 2802

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focus...

2025-09-11 20:00 3603

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused...

2025-08-01 20:00 5516

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preli...

2025-07-09 20:00 4043

Latest News